NovaScan announces Luminary Scientific Advisory Board Leaders in Pulmonary and Gastroenterology
Chicago IL: NovaScan, a clinical-stage oncology company based in Chicago, has announced the appointment of a luminaries in gastroeneterology to lead initiatives in GI. NovaScan’s gastroenterology Scientific Advisory Board will be led by Dr Isaac Raijman, AGAF, FASGE,...
NovaScan Lung Studies Published in a Leading Peer Reviewed Journal
NovaScan, a clinical-stage oncology company based in Chicago and Milwaukee, recently had its publication titled "The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and ex vivo Patient Studies" accepted in the highly...
NovaScan Completes $8MM Series B Financing
CHICAGO, IL, USA, November 17, 2021 /EINPresswire.com/ -- NovaScan, a clinical stage oncology company pioneering a new low cost point of care platform for cancer detection and treatment, announced that it has completed a $8 Million Series B financing, led by Builders...
NovaScan Fully Subscribes and Completes $3MM Financing
NovaScan, an emerging oncology company based in Chicago and Milwaukee, has announced that it has completed a $3MM financing. The convertible note financing was originally targeted for $2MM, but demand exceeded that amount and the company opportunistically added...
NovaScan Study on Cancer Recurrence and the Cole Frequency Published in a Peer-Reviewed Journal
NovaScan, a clinical stage oncology company based in Chicago and Milwaukee, recently had its publication titled Cole Relaxation Frequency as a Prognostic Parameter for Breast Cancer accepted in a peer-reviewed journal, the Journal of Patient Centered Research and...
NovaScan is Awarded Two More Patents, Further Protecting Company Innovations
NovaScan, a clinical stage oncology company based in Chicago and Milwaukee, was recently awarded patents for electrical scanning across tissue and for leverage of Cole frequency measurements to predict the likelihood of cancer recurrence. Patent No. 10,758,151 is a...
NovaScan welcomes Dr Charles Link to lead efforts in targeted drug delivery and to the NovaScan Board of Directors
NovaScan, an emerging clinical stage oncology company, is pleased to announce that Charles ‘Chuck’ Link MD, FACS has joined the Board of Directors of NovaScan. Dr Link is also a member of the NovaScan Executive Committee. Additionally, Chuck will lead NovaScan’s...
NovaScan Wins First Prize and Third Place in two International Competitions
November 15, 2019 NovaScan, an oncology company based in Chicago and Milwaukee, was awarded first prize in the BioPharma category in the InnoStars competition and third prize in the Innovate Hubei International Tech and Innovation Competition (InnoHubei), both in...